how to store unreconstituted tirzepatide Compounded How to Store Tirzepatide Properly:

Yang Z, Lv Y, Yu M, Mei M, Xiang L, Zhao S, et al

RF Microneedling: Minimal downtime

Sources Eli Lilly: Your weekly Zepbound routine FDA access data: Zepbound (tirzepatide) Prescribing Information starting dose 2.5 mg once weekly (accessdata.fda.gov) FDA access data: Updated Zepbound label confirming dose escalation schedule (accessdata.fda.gov) FDA access data: Highlights of prescribing info reaffirm starting and maintenance doses (accessdata.fda.gov) Journal (NEJM): SURMOUNT1 trial showing substantial sustained weight loss at 5, 10, and 15 mg doses (PubMed/NEJM) Journal (PubMed): Substudy of SURMOUNT1 with DXA body composition data (~21.3% loss) (PubMed) Journal (PubMed): 3-year SURMOUNT1 follow-up in obese and pre-diabetic participants durable weight loss & diabetes prevention (PubMed) FDA access data: Mounjaro Prescribing Information starting dose 2.5 mg once weekly for diabetes (accessdata.fda.gov) Journal (NEJM): Headtohead trial vs semaglutide showing superior reductions in weight & waist at week 72 (NEJM DOI) Journal (AppliedClinicalTrials): SURMOUNT5 Phase IIIb headtohead trial data confirming greater weight loss over 72 weeks (AppliedClinicalTrials) Reuters: Report on diabetes risk reduction trial94% reduction in progression, ~22.9% weight loss (Reuters) Time: FDA Approval of Zepbound for Weight Loss (Time) American College of Cardiology: Tirzepatide Once Weekly for the Treatment of Obesity SURMOUNT-1 (acc.org) People using drug Mounjaro sustain weight loss over three years, trial finds (The Guardian) The Guardian: Clinical Trails: A Study of Tirzepatide in Participants With Obesity or Overweight (SURMOUNT-1) (NIH Clinal Trials) Journal (PubMed): Tirzepatide Once Weekly for the Treatment of Obesity (PubMed) FDA Label: MOUNJARO (Tirzepatide Injection) Medication Guide FDA Label: ZEPBOUND (Tirzepatide Injection) Medication Guide Important Medical Information and Disclaimers Important Current Status Update : On March 19, 2025, the FDA ended enforcement discretion for compounded tirzepatide

Yeast infections are not listed as a recognised adverse effect in the Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA), nor in the European Medicines Agency's European Public Assessment Report (EPAR) for Wegovy

After adjusting for residual confounding, the difference in weight loss between those receiving tirzepatide vs semaglutide was 2.0% (95% CI, 2.1% to 1.8%) at 3 months, 3.2% (95% CI, 3.5% to 3.0%) at 6 months, and 5.1% (95% CI, 5.8% to 4.3%) at 12 months